Sutent was developed and has been approved for two types of cancer: advanced renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). To our knowledge is has been tried on patients with Ewing sarcoma and in a few cases on DSRCT patients. In some of these cases tumor growth has stopped for a while, up to seven or eight months. Sutent is taken as pills.